A Phase IIb Randomized Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of respiratory and critical care medicine"
DOI: 10.1164/rccm.202112-2824oc
Abstract: RATIONALE Treatment options for idiopathic pulmonary fibrosis (IPF) are limited. OBJECTIVES To evaluate the efficacy and safety of BG00011, an anti-αvβ6 IgG1 monoclonal antibody, in the treatment of patients with IPF. METHODS In a phase… read more here.
Keywords: monoclonal antibody; idiopathic pulmonary; phase iib; pulmonary fibrosis ... See more keywords